Key result
Agonist-induced VSMC contraction rapidly increases SMII filament assembly and stabilizes exchange kinetics.
Why the study?
Precisely how smooth muscle myosin 2 filaments assemble and exchange in living smooth muscle cells at steady state and during induced contractility remained poorly defined.
Does agonist-induced contractility alter SMII filament assembly and exchange kinetics in vascular smooth muscle cells?
Does agonist-induced contractility alter SMII filament assembly and exchange kinetics in vascular smooth muscle cells?
SMII is a highly dynamic contractile scaffold in vascular smooth muscle cells, and its rapid assembly and stabilization during contraction provide a new mechanistic layer for understanding vascular tone and arterial stiffness.
SMII dynamics may inform vascular tone mechanisms; leaves open translation to human arterial stiffness or hypertension therapies.
BACKGROUND: Vascular smooth muscle cells (SMCs) dynamically tune blood vessel diameter to regulate blood pressure, provide vessel wall structural integrity, and absorb shock on a beat-to-beat timescale. SMII (smooth muscle myosin 2) is the dominant motor protein driving SMC contraction. To function, SMII monomers dynamically assemble into filaments, which associate with the actin cytoskeleton to drive contractility. Precisely how SMII filaments assemble and exchange in living SMCs, however, both at steady state and during induced contractility, remains poorly defined. METHODS: We used a single-cell filament assembly assay to determine SMII assembly into filaments at steady state and upon induced contractility in rat aortic SMCs (A7r5) transiently expressing EGFP (enhanced green fluorescent protein)-tagged SM1A (SMII isoform 1A). We then used fluorescence recovery after photobleaching (FRAP) to characterize SMII exchange kinetics at steady state and upon induced contractility, and measured changes in force production using traction force microscopy. Finally, we developed a knock-in EGFP-SMII murine model to quantify SMII dynamics at endogenous expression in primary SMCs and intact arterioles. RESULTS: While predominantly filamentous at baseline, induced contraction rapidly increased SMII filament assembly. Fluorescence recovery after photobleaching revealed rapid SMII exchange kinetics, more similar to nonmuscle myosin II than striated myosin II, and induced contractility consistently stabilized SMII filaments. Super-resolution imaging revealed SMII and nonmuscle myosin II filament structures consistent with coassembly. Endogenous EGFP-SMII in primary SMCs and intact arterioles paralleled cell culture studies with similar baseline exchange kinetics and activation-dependent stabilization. CONCLUSIONS: Together, these data support a model in which SMII is surprisingly dynamic and coassembles with nonmuscle myosin II. Vascular SMC activation further increases SMII filament assembly while reducing filament exchange, consistent with stabilization of a dynamic SMII pool during force generation, thereby allowing cells to dynamically adapt their overall contractility in response to environmental conditions.
No takes yet. Share an insight, caveat, or question.
Demeulenaere et al. (2026) studied Vascular smooth muscle cell physiology (preclinical model). Agonist-induced contractility (carbachol or angiotensin II) vs. Baseline (steady state prior to agonist application) was evaluated on SMII filament assembly and exchange kinetics (mobile fraction and t1/2). Agonist-induced contraction of vascular smooth muscle cells rapidly increased SMII filament assembly and stabilized SMII exchange kinetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: